SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 191 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2024. The put-call ratio across all filers is 0.59 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,443,168 | +101.3% | 167,714 | +133.3% | 0.07% | +94.3% |
| Q1 2024 | $1,710,815 | -5.1% | 71,883 | -13.9% | 0.04% | +20.7% |
| Q4 2023 | $1,803,484 | -34.0% | 83,456 | -55.6% | 0.03% | -44.2% |
| Q3 2023 | $2,731,357 | -13.1% | 188,110 | +25.2% | 0.05% | -16.1% |
| Q2 2023 | $3,143,602 | +14.9% | 150,196 | +16.0% | 0.06% | +12.7% |
| Q1 2023 | $2,735,547 | – | 129,524 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 2,168,691 | $30,297,000 | 13.16% |
| Boxer Capital, LLC | 234,220 | $3,272,000 | 0.78% |
| SPHERA FUNDS MANAGEMENT LTD. | 296,310 | $4,139,000 | 0.70% |
| Ghost Tree Capital, LLC | 200,000 | $2,794,000 | 0.58% |
| Eventide Asset Management | 225,000 | $3,143,000 | 0.20% |
| Vident Investment Advisory, LLC | 103,558 | $1,447,000 | 0.12% |
| J. Goldman & Co LP | 147,181 | $2,056,000 | 0.11% |
| TIVERTON ASSET MANAGEMENT LLC | 137,732 | $1,924,000 | 0.10% |
| Crestline Management, LP | 55,368 | $773,000 | 0.10% |
| Tekla Capital Management LLC | 200,000 | $2,794,000 | 0.10% |